Epcoritamab + R-CHOP Cuts DLBCL Progression Risk by 51% in Phase 3
GMAB sits 52% above its 52-week low of $23.62.
Summary
Genmab and AbbVie's Phase 3 EPCORE DLBCL-2 trial hit its primary endpoint: epcoritamab plus R-CHOP reduced the risk of progression or death by 51% (HR 0.49, p<0.0001) versus R-CHOP alone in newly diagnosed DLBCL patients with IPI 2-5. This is the first Phase 3 bispecific antibody combination to show a statistically significant PFS benefit in this frontline setting, potentially reshaping the standard of care. The safety profile was consistent with prior data. Genmab's stock is trading near its 52-week high, and this news follows positive Phase 2 data for Rina-S in ovarian cancer just two days ago, reinforcing the company's late-stage pipeline momentum. Regulatory submissions are next; data will be presented at a future medical meeting.
At the time of this announcement, GMAB was trading at $35.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.2B. The 52-week trading range was $23.62 to $37.15. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: BusinessWire.